Últimas noticias sobre TROOPS (NASDAQ:TROO) Bolsa

TROOPS

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

TROOPS Inc

Jefferies analyst James Wheatcroft reinstates Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy and announces $380 price target.

News

Price Target

Initiation

Analyst Ratings

FLUT

Jefferies Reinstates Buy on Flutter Entertainment, Announces $380 Price Target

Looking ahead to 2026, Soligenix is positioning itself for a pivotal year marked by key clinical milestones and potential catalysts across its rare disease pipeline. Most notably, the company anticipates releasing top-line results from its confirmatory Phase 3 FLASH2 trial of HyBryte&#x2122; for early-stage cutaneous T-cell lymphoma in the second half of the year. With enrollment on track and prior data showing promising efficacy and safety, the outcome of FLASH2 could be transformational for HyBryte's regulatory and commercial trajectory. Soligenix is also actively exploring strategic partnerships and M&amp;A opportunities to maximize value creation, while targeting global marketing authorizations. Backed by a diversified pipeline, solid early clinical data, and an expanding manufacturing footprint, the company sees 2026 as a potential inflection point in its mission to deliver impactful therapies for underserved patient populations.
&nbsp;
&nbsp;

SNGX

Soligenix Issues Corporate Update Highlighting FLASH2 Phase 3 Progress, Psoriasis and Behçet's Trial Milestones, and Strategic Outlook Through 2026

ARWR

Arrowhead Pharmaceuticals Doses First Patient In Pivotal YOSEMITE Phase 3 Trial Of RNAi-Based Zodasiran For Homozygous Familial Hypercholesterolemia

WIIM

BCTX

BriaCell shares are trading higher after the company reported a 52% one-year survival rate in its Phase 2 metastatic breast cancer trial.

Jefferies analyst Surinder Thind downgrades WNS (Holdings) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) from Buy to Hold and lowers the price target from $80 to $76.5.

Downgrades

Jefferies Downgrades WNS (Holdings) to Hold, Lowers Price Target to $76.5

LakeShore Biopharma shares are trading higher after the company announced a $15 million private placement financing.

BriaCell Reports 52% One-Year Survival in Phase 2 Metastatic Breast Cancer Trial, Surpassing Standard of Care in Heavily Pre-Treated Patients

Financing

LakeShore Biopharma Enters $15M Share And Warrant Purchase Agreement With Institutional Investor

Martin Marietta  Appoints Michael J. Petro as Chief Financial Officer, Succeeding Interim CFO Robert J. Cardin Effective Immediately

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

SLNH

Soluna Holdings Announces 30 MW Expansion With A Bitcoin Miner At Dorothy 2 Site

NDRA: 156% &#x7C; <a href="https://www.benzinga.com/node/46285134">ENDRA Life Sciences shares are trading higher after the company announced it will be granted a US patent titled "Radio Frequency Applicator".</a>
&nbsp;
PROK: 158% &#x7C; <a href="https://www.benzinga.com/node/46292228">ProKidney shares are trading higher after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.</a>
&nbsp;
LASE: 51% &#x7C; <a href="https://www.benzinga.com/node/46285555">Laser Photonics shares are trading higher after the company reported a year-over-year increase in Q1 revenue results.</a>

Movers

Trading Ideas

LASE

NDRA

PROK

Market-Moving News for July 8th

Colliers Securities analyst Barry Oxford initiates coverage on Bluerock Homes Trust (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BHM#AMEX">BHM</a>) with a Buy rating and announces Price Target of $15.

Bluerock Homes Trust, Inc. Class A Common Stock

Colliers Securities Initiates Coverage On Bluerock Homes Trust with Buy Rating, Announces Price Target of $15

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $50 price target.

Reiteration

URGN

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $50 Price Target

Biotech

General

PSTV

Plus Therapeutics Announces Treatment Of Initial Patients In ReSPECT-LM Dose Optimization Trial Of REYOBIQ In Leptomeningeal Metastases

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) reported a sharp rise in <a target="_blank" href="https://www.benzinga.com/topic/alibaba" rel="noreferrer noopener">on-demand delivery transactions</a>, with combined daily orders on its platforms, Taobao Instant Commerce and Ele.me, reaching 80 million. This information was shared in a Monday post on Alibaba&#8217;s official WeChat account, <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3317275/taobaos-daily-demand-orders-soar-chinas-instant-e-commerce-war-heats" rel="noreferrer noopener">as</a> reported by the South China Morning Post.
Taobao Instant Commerce, launched in late April, gained traction quickly. It hit 10 million daily orders in its first week and 40 million within a month, then jumped from 60 to 80 million in just 12 days amid summer promotions and subsidies.
The platform&#8217;s daily active users have now surpassed 200 million, signaling Alibaba&#8217;s intensified efforts to compete with rivals like Meituan (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGF#OTC">MPNGF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>) and JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) in the rapidly expanding instant delivery market.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/46091793/chinas-food-delivery-war-heats-up-as-jd-com-recruits-thousands-of-full-time-riders" rel="noreferrer noopener">China&#8217;s Food Delivery War Heats Up As JD.com Recruits Thousands Of Full-Time Riders</a>
In the ongoing competition, Meituan, a major player in the food delivery sector, reported 120 million daily transactions on Saturday, leading to brief server overloads as food and retail order volumes peaked during high-demand periods. Meituan maintains a steady hold on its 70% market share in domestic food delivery.
Alibaba&#8217;s strategic push into on-demand delivery is further evidenced by its commitment of a 50 billion yuan (approximately $7 billion) subsidy program for consumers and merchants over the next year. This program is designed to accelerate growth beyond Alibaba&#8217;s traditional e-commerce business.
To streamline operations and enhance its competitive edge against Meituan and JD.com, Alibaba integrated Ele.me and Fliggy into its <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/46047699/alibaba-integrates-ele-me-and-fliggy-into-core-business-to-battle-rivals-in-delivery-war" rel="noreferrer noopener">core e-commerce unit</a> in June.
Analysts from Jefferies told the SCMP that Alibaba now focuses on integrating food delivery, instant commerce, and traditional retail to maximize synergies across segments.
Alibaba stated that the rapid expansion of Taobao Instant Commerce has contributed to a doubling of China&#8217;s total daily instant delivery orders across different platforms from around 100 million in May to 200 million.
Investors have shown optimism, pushing Alibaba and other Chinese stocks higher on Tuesday, largely in anticipation of the upcoming U.S. tariff deadline.
According to a report from Elara <a target="_blank" href="https://www.cnbctv18.com/market/stocks/global-investors-are-flocking-to-chinese-stocks-ahead-of-us-tariffs-deadline-19632525.htm" rel="noreferrer noopener">cited</a> by CNBC, Chinese equities saw $2.4 billion in inflows last week alone. This trend is part of a larger pattern, with emerging market funds attracting over $6 billion in the past three weeks, marking the fastest inflow pace since January 2023.
President Donald Trump had initially set a July 9 deadline for various countries to finalize trade deals to avoid higher tariff rates. However, the White House confirmed that President Trump will sign an executive order to delay this deadline to August 1, 2025. This three-week reprieve is intended to allow more time for trade negotiations, as the administration aims to secure favorable trade deals.
Price Action:&nbsp;BABA shares are trading higher by&nbsp;2.40% to&nbsp;$108.82 premarket at&nbsp;last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46250853/alibabas-ai-and-cloud-moves-have-sparked-28-stock-rebound" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s AI And Cloud Moves Have Sparked 28% Stock Rebound</a></li>
</ul>
Photo by Robert Way via Shutterstock

Asia

Tech

Media

BABA

MPNGF

MPNGY

Alibaba's Delivery Ambition Sets Stage For China's Epic Clash Of Giants

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $75 price target.

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $75 Price Target

MBAV

Trading Halt: Halted at 7:27:20 a.m. ET - Trading Halt: Halt News Pending

MBAVW

MBAVU

WestPark Capital analyst Casey Ryan initiates coverage on Data I/O (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIO#NASDAQ">DAIO</a>) with a Buy rating and announces Price Target of $5.22.

DAIO

WestPark Capital Initiates Coverage On Data I/O with Buy Rating, Announces Price Target of $5.22

Insurance

Press Releases

Real Estate

TROOPS, Inc. (Nasdaq: TROO) Explores Acquisition of Hong Kong Insurance Brokerage and Nears Agreement to Acquire Bestfaith International Technology Limited

WANG AND LEE GROUP, INC. ANNOUNCES STRATEGIC INVESTMENT IN TROOPS, INC. TO DRIVE INNOVATION IN SMART BUILDING SOLUTIONS AND EXPAND ESG TOKEN REWARD ECOSYSTEM

Fintech

Commodities

TROOPS, INC. ANNOUNCES RECEIPT OF INITIAL PAYMENT TOWARD STRATEGIC INVESTMENT BY WANG & LEE GROUP, INC.

TROOPS, Inc. (Nasdaq: TROO) Announces Update on Hong Kong High Court Judgment and Explores Strategic Legal Options to Safeguard Shareholder Interests

TROO

WLGS

Astrotech

Coda Octopus Group

Electro-Sensors

Focus Universal

Frequency Electronics, Inc. - Common Stock

Frequency Electronics

Identiv

AEye

Interlink Electronics, Inc. - Common Stock

Interlink Electronics

LightPath Technologies, Inc. - Class A Common Stock

LightPath Technologies

908 Devices

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

NOVONIX Limited - American Depository Shares

NOVONIX

Research Frontiers Incorporated - Common Stock

Research Frontiers

SmartRent

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

Sono-Tek

ScanTech AI Systems

Unusual Machines

Universal Security Instruments, Inc. Common Stock

Universal Security

VerifyMe

Vuzix

Wrap Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Zepp Health

Comments

TROOPS

Noticias

Últimas noticias sobre TROOPS (NASDAQ:TROO) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL